An adaptive biomarker strategy clinical trial design
نویسندگان
چکیده
منابع مشابه
An adaptive biomarker strategy clinical trial design
The Biomarker Strategy Design has been proposed for trials assessing the value of a biomarker in guiding treatment in oncology. In such trials, patients are randomised to a control arm, receiving the standard chemotherapy treatment, or a biomarker-directed treatment arm, when biomarker status is used to guide treatment. The randomised groups are then compared, often using a noninferiority test ...
متن کاملAdaptive enrichment in biomarker-stratified clinical trial design
In Phase II oncology trials, targeted therapies are being constantly evaluated for their efficacy in specific populations of interest. Such trials require designs that allow for stratification based on the participants’ biomarker signature. One of the disadvantages of a targeted design (defined as enrichment in biomarker-positive sub-population) is that if the drug has at least some activity in...
متن کاملBiomarker based clinical trial design.
The established molecular heterogeneity of human cancers and the subsequent stratification of conventional diagnostic categories require the development of new paradigms for the development of a reliable basis for predictive medicine. We review clinical trial designs for the development of new therapeutics and predictive biomarkers to inform their use. We cover designs for a wide range of setti...
متن کاملAdaptive Clinical Trial Design
Adaptive design is usually defined as the use of accumulating data obtained during the conduct of the trial to decide how to modify aspects of the trial as it progresses, without affecting its validity and integrity (Gallo et al., 2006). This form of research design involves a prospectively planned opportunity to modify the parameters of the study based on analysis of interim data while the stu...
متن کاملBiomarker informed adaptive clinical trial designs
In adaptive design clinical trials, an endpoint at the final analysis that takes a long time to observe is not feasible to be used for making decisions at the interim analysis. For example, overall survival (OS) in oncology trials usually cannot be used to make interim decisions. However, biomarkers correlated to the final clinical endpoint can be used. Hence, considerable interest has been dra...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Trials
سال: 2013
ISSN: 1745-6215
DOI: 10.1186/1745-6215-14-s1-o103